nitrites has been researched along with Vascular Diseases in 36 studies
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Examples of agents implicated include anorexients, ergotamine, mercury, arsenic, vinyl chloride, thorotrast, plant alkaloids, nitrites, toxic oil, tryptophan and bacterial, viral and parasitic infections." | 4.80 | Epidemics of vascular toxicity and pulmonary hypertension: what can be learned? ( Egermayer, P, 2000) |
| "Nitric oxide (NO) is a potent vasodilator in the lung, whose bioavailability and signaling pathway are impaired in PAH." | 2.49 | Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics. ( Bueno, M; Gladwin, MT; Mora, AL; Wang, J, 2013) |
| "Periodontitis was induced in mice by placement of a ligature for 14 days around the second molar." | 1.91 | Local delivery of nitric oxide prevents endothelial dysfunction in periodontitis. ( Ahluwalia, A; Barnes, MR; Curtis, M; D'Aiuto, F; Fernandes, D; Foster, J; Gee, LC; Goddard, A; Godec, T; Khambata, RS; Massimo, G; Orlandi, M; Ruivo, E; Wade, WG, 2023) |
| " Meanwhile, a most appropriate match of prescription dosage for curing vascular disease was got, which was based on NO value of pharmacodynamics experimental data and the endothelial cells configuration which would changed in a degree when damaged by hydration diamine." | 1.32 | A new experimental design for screening Chinese medicine formula. ( Bo-Chu, W; Chun-Hong, T; Li, Z; Qi, C; Shao-Xi, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (41.67) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 8 (22.22) | 29.6817 |
| 2010's | 7 (19.44) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Morishima, T | 1 |
| Iemitsu, M | 1 |
| Fujie, S | 1 |
| Ochi, E | 1 |
| Namwong, A | 1 |
| Kumphune, S | 1 |
| Seenak, P | 1 |
| Chotima, R | 1 |
| Nernpermpisooth, N | 1 |
| Malakul, W | 1 |
| Fernandes, D | 1 |
| Khambata, RS | 1 |
| Massimo, G | 1 |
| Ruivo, E | 1 |
| Gee, LC | 1 |
| Foster, J | 1 |
| Goddard, A | 1 |
| Curtis, M | 1 |
| Barnes, MR | 1 |
| Wade, WG | 1 |
| Godec, T | 1 |
| Orlandi, M | 1 |
| D'Aiuto, F | 1 |
| Ahluwalia, A | 1 |
| Feenstra, L | 1 |
| Kutikhin, AG | 1 |
| Shishkova, DK | 1 |
| Buikema, H | 1 |
| Zeper, LW | 1 |
| Bourgonje, AR | 1 |
| Krenning, G | 1 |
| Hillebrands, JL | 1 |
| Majumdar, AS | 1 |
| Joshi, PA | 1 |
| Giri, PR | 1 |
| Lukkhananan, P | 1 |
| Thawonrachat, N | 1 |
| Srihirun, S | 1 |
| Swaddiwudhipong, W | 1 |
| Chaturapanich, G | 1 |
| Vivithanaporn, P | 1 |
| Unchern, S | 1 |
| Visoottiviseth, P | 1 |
| Sibmooh, N | 1 |
| Weaver, JL | 1 |
| Snyder, R | 1 |
| Knapton, A | 1 |
| Herman, EH | 1 |
| Honchel, R | 1 |
| Miller, T | 1 |
| Espandiari, P | 1 |
| Smith, R | 1 |
| Gu, YZ | 1 |
| Goodsaid, FM | 1 |
| Rosenblum, IY | 1 |
| Sistare, FD | 1 |
| Zhang, J | 1 |
| Hanig, J | 1 |
| Kaur, J | 1 |
| Reddy, K | 1 |
| Balakumar, P | 2 |
| Gentner, NJ | 1 |
| Weber, LP | 1 |
| Alef, MJ | 1 |
| Tzeng, E | 1 |
| Zuckerbraun, BS | 1 |
| Bueno, M | 1 |
| Wang, J | 1 |
| Mora, AL | 1 |
| Gladwin, MT | 1 |
| Kathuria, S | 1 |
| Mahadevan, N | 1 |
| MARCHE, J | 1 |
| FOLEY, WT | 1 |
| MCDEVITT, E | 1 |
| TULLOCH, JA | 1 |
| TUNIS, M | 1 |
| WRIGHT, IS | 1 |
| D'ARDES, V | 1 |
| KRAUCHER, GK | 1 |
| HUEBER, EF | 1 |
| THALER, H | 1 |
| WICK, E | 1 |
| SAMUELS, SS | 2 |
| RADO, JP | 1 |
| GONDA, E | 1 |
| KOVACS, E | 1 |
| DE LA PIERRE, M | 1 |
| BARBERA, G | 1 |
| COSTA, P | 1 |
| ABRAMSON, DI | 1 |
| SCHOGER-VSCHOLZ, I | 1 |
| SCHOGER, GA | 1 |
| KOLLMANN, HJ | 1 |
| PADERNACHT, ED | 1 |
| Migliacci, R | 1 |
| Falcinelli, F | 1 |
| Imperiali, P | 1 |
| Floridi, A | 1 |
| Nenci, GG | 1 |
| Gresele, P | 1 |
| Chun-Hong, T | 1 |
| Bo-Chu, W | 1 |
| Qi, C | 1 |
| Li, Z | 1 |
| Shao-Xi, C | 1 |
| Meadows, GE | 1 |
| Kotajima, F | 1 |
| Vazir, A | 1 |
| Kostikas, K | 1 |
| Simonds, AK | 1 |
| Morrell, MJ | 1 |
| Corfield, DR | 1 |
| Shah, DI | 1 |
| Singh, M | 1 |
| Lalu, MM | 1 |
| Cena, J | 1 |
| Chowdhury, R | 1 |
| Lam, A | 1 |
| Schulz, R | 1 |
| Baccarani, A | 1 |
| Yasui, K | 1 |
| Olbrich, KC | 1 |
| El-Sabbagh, A | 1 |
| Kovach, S | 1 |
| Follmar, KE | 1 |
| Erdmann, D | 1 |
| Levin, LS | 1 |
| Stamler, JS | 1 |
| Klitzman, B | 1 |
| Zenn, MR | 1 |
| Ferlito, S | 1 |
| Gallina, M | 1 |
| Catassi, S | 1 |
| Bisicchia, A | 1 |
| Di Salvo, M | 1 |
| Murohara, T | 1 |
| Kugiyama, K | 1 |
| Ota, Y | 1 |
| Doi, H | 1 |
| Ogata, N | 1 |
| Ohgushi, M | 1 |
| Yasue, H | 1 |
| Egermayer, P | 1 |
| Iriuchijima, J | 1 |
| Bartolo, M | 1 |
| Gambelli, G | 1 |
| Tomei, F | 1 |
| Madorskiĭ, VA | 1 |
| Voronin, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose Escalation Study to Evaluate the Effect of Inhaled Nitrite on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Hypertension[NCT01431313] | Phase 2 | 48 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basal platelet oxygen consumption measured in isolated platelets by extracellular flux analysis (XF24, Seahorse Biosciences, Billerica, MA). (NCT01431313)
Timeframe: Maximal effect at 15 minutes post 45mg or 90mg inhalation vs Pre dose
| Intervention | picomoles O2/min (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -17.58 |
| WHO Group II Pulmonary Hypertension (PH) | 8.62 |
| WHO Group III Pulmonary Hypertension (PH) | -11.64 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of plasma nitrite concentrations in mixed venous blood over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.9 |
| WHO Group II Pulmonary Hypertension (PH) | 7.0 |
| WHO Group III Pulmonary Hypertension (PH) | 7.4 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of pulmonary artery occlusion (capillary) pullback nitrite concentration over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Pre-dose, 15 minutes post 45mg and 90mg inhalation
| Intervention | micromolar (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 9.2 |
| WHO Group III Pulmonary Hypertension (PH) | 2.4 |
Characteristic impedance (Zc) which may be related to compliance effects in the large, conduit arteries. (NCT01431313)
Timeframe: Pre dose and 60 minutes post last dosage inhaled
| Intervention | dyne*sec/cm5 (Median) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.004 |
| WHO Group II Pulmonary Hypertension (PH) | -0.34 |
| WHO Group III Pulmonary Hypertension (PH) | -0.20 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since pulmonary vascular resistance (PVR) was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of PVR over all subsequent times and doses (beta from the mixed effects model, converted back from natural log to Woods units), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | Woods units (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 0.77 |
| WHO Group II Pulmonary Hypertension (PH) | 0.40 |
| WHO Group III Pulmonary Hypertension (PH) | -0.39 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. The reported mean is the change from baseline of MAP over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -5.1 |
| WHO Group II Pulmonary Hypertension (PH) | -3.4 |
| WHO Group III Pulmonary Hypertension (PH) | -9.5 |
Linear mixed effects model across all time points and doses relative to baseline. The mixed effects model takes into account all time points combined (repeated measures) and has been extensively described for clinical trials (please see references). In this model, the effect of treatment on hemodynamics (measured at 0, 15, 30, 45, and 60 minutes after 45mg followed by same times after 90 mg dose) was compared with baseline values. We assessed the overall linear trend of treatment. The effect of treatment on hemodynamics in each patient group was assessed separately in mixed-effects models. Since systemic vascular resistance was not normally distributed, it was transformed to natural log prior to analysis. The reported mean is the change from baseline of SVR over all subsequent times and doses (beta from the mixed effects model), and is reported as the mean and 95% confidence interval. (NCT01431313)
Timeframe: Time zero, 15, 30, 45 and 60 minutes after nebulization of 45mg followed by 90 mg dose
| Intervention | mmHg⋅min/L (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | -0.43 |
| WHO Group II Pulmonary Hypertension (PH) | 1.19 |
| WHO Group III Pulmonary Hypertension (PH) | -2.04 |
Time in minutes to maximum PVR decrease. During study procedure, hemodynamics were measured at 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose. The time point at which each patient's maximal decrease in PVR occurred was recorded and reported as the mean and standard deviation in each cohort. (NCT01431313)
Timeframe: 0, 15, 30, 45, and 60 minutes after 45 mg followed by same times after 90 mg dose
| Intervention | minutes (Mean) |
|---|---|
| WHO Group I Pulmonary Arterial Hypertension (PAH) | 42.0 |
| WHO Group II Pulmonary Hypertension (PH) | 33.0 |
| WHO Group III Pulmonary Hypertension (PH) | 42.5 |
3 reviews available for nitrites and Vascular Diseases
| Article | Year |
|---|---|
Nitric oxide and nitrite-based therapeutic opportunities in intimal hyperplasia.
Topics: Animals; Humans; Hyperplasia; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Tunica Intima; | 2012 |
Nitrite signaling in pulmonary hypertension: mechanisms of bioactivation, signaling, and therapeutics.
Topics: Animals; Humans; Hypertension, Pulmonary; Nitrates; Nitric Oxide; Nitrites; Signal Transduction; Vas | 2013 |
Epidemics of vascular toxicity and pulmonary hypertension: what can be learned?
Topics: Appetite Depressants; Arsenic; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reacti | 2000 |
1 trial available for nitrites and Vascular Diseases
| Article | Year |
|---|---|
Prior beetroot juice ingestion offsets endothelial dysfunction following prolonged sitting.
Topics: Beta vulgaris; Blood Pressure; Dietary Supplements; Double-Blind Method; Eating; Female; Fruit and V | 2022 |
32 other studies available for nitrites and Vascular Diseases
| Article | Year |
|---|---|
Pineapple fruit improves vascular endothelial dysfunction, hepatic steatosis, and cholesterol metabolism in rats fed a high-cholesterol diet.
Topics: Ananas; Animals; Antioxidants; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Diet; Fatty Liver; Frui | 2022 |
Local delivery of nitric oxide prevents endothelial dysfunction in periodontitis.
Topics: Animals; Endothelium, Vascular; Mice; Nitrates; Nitric Oxide; Nitrites; Periodontitis; Vascular Dise | 2023 |
Calciprotein Particles Induce Endothelial Dysfunction by Impairing Endothelial Nitric Oxide Metabolism.
Topics: Animals; Endothelium; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Nitric | 2023 |
Resveratrol attenuated smokeless tobacco-induced vascular and metabolic complications in ovariectomized rats.
Topics: Animals; Aorta; Collagen; Diabetes Complications; Diabetes Mellitus; Estradiol; Female; Glucose Tole | 2013 |
Endothelial dysfunction in subjects with chronic cadmium exposure.
Topics: Arginine; Biomarkers; Cadmium Compounds; Endothelium, Vascular; Environmental Exposure; Female; Glut | 2015 |
Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385.
Topics: Animals; Biomarkers; Blood Vessels; Clinical Chemistry Tests; Cyclic N-Oxides; Dose-Response Relatio | 2008 |
The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat.
Topics: Animals; Arsenites; Cholesterol; Endothelium, Vascular; Fenofibrate; Hypolipidemic Agents; In Vitro | 2010 |
Secondhand tobacco smoke, arterial stiffness, and altered circadian blood pressure patterns are associated with lung inflammation and oxidative stress in rats.
Topics: Animals; Blood Pressure; Circadian Rhythm; Endothelium, Vascular; Male; Nitrates; Nitric Oxide; Nitr | 2012 |
Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.
Topics: Anilides; Animals; Endothelium, Vascular; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductas | 2013 |
[Therapy of vascular syndromes, particularly arteriolar, with pentaerythritol tetranitrate].
Topics: Nitrites; Pentaerythritol Tetranitrate; Peripheral Vascular Diseases; Syndrome; Vascular Diseases | 1952 |
Studies of vasospasm. I. The use of glyceryl trinitrate as a diagnostic test of peripheral pulses.
Topics: Cardiovascular Physiological Phenomena; Diagnostic Tests, Routine; Heart Rate; Humans; Nitrites; Nit | 1953 |
[Degenerative vascular diseases; clinico-experimental study].
Topics: Blood Vessels; Disease; Gonadal Steroid Hormones; Humans; Nitrites; Vascular Diseases; Vitamin E | 1953 |
[Therapy of peripheral circulatory disorders with tetraethylammonium nitrite].
Topics: Cardiovascular Diseases; Nitrites; Peripheral Vascular Diseases; Tetraethylammonium; Vascular Diseas | 1953 |
[Peripheral arterial circulatory disorders and therapy. I. Rheoangiographic registration of the effect of nitroglycerin preparations in healthy subjects].
Topics: Healthy Volunteers; Nitrites; Nitroglycerin; Peripheral Arterial Disease; Peripheral Vascular Diseas | 1956 |
Sustained-action peritrate in arterial insufficiency of the lower extremities.
Topics: Lower Extremity; Nitrites; Pentaerythritol Tetranitrate; Peripheral Vascular Diseases; Vascular Dise | 1958 |
The role of venous constriction in circulatory disorders.
Topics: Cardiovascular Diseases; Constriction; Constriction, Pathologic; Heart Failure; Nitrites; Vascular D | 1958 |
[Variations of oscillometric indices of the extremities induced by nitroglycerin in healthy subjects and in arteriopathic patients].
Topics: Extremities; Healthy Volunteers; Humans; Nitrites; Nitroglycerin; Peripheral Vascular Diseases; Vasc | 1959 |
DRUGS USED IN PERIPHERAL VASCULAR DISEASES.
Topics: Deoxyribonuclease I; Dihydroergotoxine; Endopeptidases; Ergot Alkaloids; Ganglionic Blockers; Histam | 1963 |
[THE TREATMENT OF DISORDERS OF PERIPHERAL BLOOD FLOW IN PRACTICE].
Topics: Acetylcholine; Blood Circulation; Blood Volume Determination; Bloodletting; Delayed-Action Preparati | 1963 |
[Treatment of spastic vascular diseases].
Topics: Alkaloids; Atropa belladonna; Barbiturates; Humans; Muscle Spasticity; Nitrites; Papaverine; Parasym | 1955 |
Peritrate in peripheral arterial diseases.
Topics: Nitrites; Pentaerythritol Tetranitrate; Peripheral Arterial Disease; Peripheral Vascular Diseases; V | 1952 |
Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Cyclic GMP; Diastole; Endothelium, Vascular; Female; Homocy | 2004 |
A new experimental design for screening Chinese medicine formula.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Chinese Herb | 2004 |
Overnight changes in the cerebral vascular response to isocapnic hypoxia and hypercapnia in healthy humans: protection against stroke.
Topics: Adult; Brain; Cerebrovascular Circulation; Humans; Hypercapnia; Hypoxia; Ischemia; Male; Middle Cere | 2005 |
Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
Topics: Animals; Blood Pressure; Endothelins; Lipid Metabolism; Male; Microscopy, Electron, Scanning; Nitrat | 2006 |
Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction.
Topics: Animals; Aorta, Thoracic; Blotting, Western; Collagenases; Endotoxemia; Endotoxins; Gelatinases; In | 2006 |
Efficacy of ethyl nitrite in reversing surgical vasospasm.
Topics: Animals; Laser-Doppler Flowmetry; Male; Nitrites; Prodrugs; Rats; Rats, Inbred Strains; Regional Blo | 2007 |
Nitrite plasma levels in normolipemic and hypercholesterolemic arteriopathics after vasoactive and lipid-lowering treatment.
Topics: Aged; Arteries; Female; Fibrinolytic Agents; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lip | 1999 |
Effects of atrial and brain natriuretic peptides on lysophosphatidylcholine-mediated endothelial dysfunction.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Atrial Natriuretic Factor; Cattle; Coronary Vessels | 1999 |
Effects of nitrites on arterial collateral vessels of dogs.
Topics: Animals; Arteries; Blood Pressure; Carotid Arteries; Collateral Circulation; Dogs; Female; Femoral A | 1971 |
[Significance and value of the nitrite test in angiology].
Topics: Arteriosclerosis; Diabetic Angiopathies; Humans; Methods; Nitrites; Nitroglycerin; Plethysmography, | 1971 |
[On the clinical aspects of the combined effect of sodium nitrite and triethanolamine].
Topics: Adult; Air Pollution; Amino Alcohols; Central Nervous System Diseases; Cerebrovascular Disorders; Fe | 1968 |